Taiwan Liposome Company (TLC) is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic conditions, and infectious diseases. Headquartred in Taiwan, the firm has facilities in South San Francisco, CA. The Company's anticancer medicine product named Lipo-Dox has been distributed in domestic markets. The Company authorizes another company to involve in the manufacturing and distribution of Lipo-Dox. The major clients of Lipo-Dox are oncology departments of medical centers. During the year ended December 31, 2011, the Company obtained approximately 63.79% and 36.21% of its total revenue from technology authorization and copyright revenue, respectively
